key: cord-0773414-s4giw66s
authors: Patchen, B. K.; Clark, A. G.; Gaddis, N. M.; Hancock, D. B.; Cassano, P. A.
title: Genetically predicted serum vitamin D and COVID-19: a Mendelian randomization study
date: 2021-02-01
journal: nan
DOI: 10.1101/2021.01.29.21250759
sha: e0b239c824cd8d716332d534f7edf468979f99a6
doc_id: 773414
cord_uid: s4giw66s

Objectives: To investigate causality of the association of serum vitamin D with the risk and severity of COVID-19 infection. Design: Two-sample Mendelian randomization study. Setting: Summary data from genome-wide analyses in the population-based UK Biobank and SUNLIGHT Consortium, applied to meta-analyzed results of genome-wide analyses in the COVID-19 Host Genetics Initiative. Participants: 17,965 COVID-19 cases including 11,085 laboratory or physician confirmed cases, 7,885 hospitalized cases, and 4,336 severe respiratory cases, and 1,370,547 controls, primarily of European ancestry. Exposures: Genetically predicted variation in serum vitamin D status, based on genome-wide significant single nucleotide polymorphisms (SNPs) associated with serum vitamin D or risk of vitamin D deficiency/insufficiency. Main outcome measures: Susceptibility to and severity of COVID-19 infection, including severe respiratory infection and hospitalization. Results: Mendelian randomization analysis, powered to detect moderate effects comparable to those seen in observational studies, provided little to no evidence for an effect of genetically predicted serum vitamin D on susceptibility to or severity of COVID-19 infection. Using SNPs in loci related to vitamin D metabolism as proxies for serum vitamin D concentration, the odds ratio for a standard deviation increase in serum vitamin D was 1.04 (95% confidence interval 0.92 to 1.18) for any COVID-19 infection versus population controls, 1.05 (0.84-1.31) for hospitalized COVID-19 versus population controls, 0.96 (0.64 to 1.43) for severe respiratory COVID-19 versus population controls, 1.15 (0.99 to 1.35) for COVID-19 positive versus COVID-19 negative, and 1.44 (0.75 to 2.78) for hospitalized COVID-19 versus non-hospitalized COVID-19. Results were similar in analyses that used all SNPs with genome-wide significant associations with serum vitamin D (i.e., including SNPs in loci with no known relationship to vitamin D metabolism) and in analyses using SNPs with genome-wide significant associations with risk of vitamin D deficiency or insufficiency. Conclusions: These findings suggest that genetically predicted differences in long-term vitamin D nutritional status do not causally affect susceptibility to and severity of COVID-19 infection, and that associations observed in previous studies may have been driven by confounding. These results do not exclude the possibility of low-magnitude causal effects, nor do they preclude potential causal effects of acute responses to therapeutic doses of vitamin D. Future directions include extension of this work to non-European ancestry populations, and high-risk populations, for example persons with comorbid disease.

supplemental oxygen, ICU admission, and death. [15] [16] [17] [18] The mounting evidence from observational 81 studies and the known effects of vitamin D on the immune system contribute to speculation 82 about whether a simple and immediate intervention like vitamin D supplementation might be 83 effective in reducing risk of COVID-19 infection or severity, but sources of guidance for 84 clinicians and the public cite a lack of evidence for a causal association. 19 Mendelian randomization (MR), a study design to address causality, uses a form of 96 instrumental variable analysis to improve causal inference and to address the biases inherent in 97 observational studies. MR uses genetic variants that are associated with the exposure (i.e., serum 98 vitamin D) as instrumental variables, or genetic instruments, that represent the long-term usual 99 exposure. Following the laws of independent assortment, genetic variants are inherited from 100 parent to offspring in a random and independent manner. An individual's genotype therefore 101 mimics the lifelong randomization of individuals into groups with different long-term serum 102 vitamin D levels. Valid MR analysis depends on three key assumptions: (1) adequate strength 103 and validity of the genetic instruments (i.e., genetic variants that underlie vitamin D 104 metabolism), (2) independence of the genetic instruments from any confounders, and (3) absence 105 of direct effects of the genetic instruments on the outcome of interest (i.e., COVID-19 status). 106 MR addresses limitations in observational data including confounding, reverse causality, and 107 measurement error, and supports triangulation on the evidence for causality when randomized 108 trials are either impossible to conduct or currently unavailable. Genome-wide association (GWA) 109 studies of serum vitamin D levels identified genetic variants that are robustly associated with 110 serum vitamin D status in different populations and ancestries. [22] [23] [24] [25] [26] [27] [28] Capitalizing on this finding, 111 researchers successfully applied MR to study associations of vitamin D with many clinical 112 outcomes, including diseases of immune system dysregulation and inflammation. [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] We used 113 MR to investigate causality of the relationship of serum vitamin D status with the risk and 114 severity of COVID-19 infection. 115

We estimated the effect of serum vitamin D levels on risk of COVID-19 infection and 118 severity with two-sample MR. 46 The associations of the genetic instruments with the exposure(s) 119 and outcome(s) were estimated in separate, independent samples, then used to calculate the MR 120 estimate of the effect of serum vitamin D status on COVID-19. 46 We used summary data from a 121 GWA study of serum vitamin D in the UK Biobank (sample 1) 22 and genome-wide data for 122 COVID-19 patients versus comparison groups from the COVID-19 Host Genetics Initiative 123 (sample 2) ( Figure 1 ). 47 Because of overlap between the UK Biobank and the COVID-19 Host 124

Genetics Initiative samples, which may bias MR results toward effects estimated from traditional 125 observational studies, 48 we replicated the analyses using summary GWAS data for serum vitamin 126 D from the SUNLIGHT Consortium. 23 We also performed sensitivity analyses to evaluate prior 127 hypotheses about the direct effect of vitamin D deficiency or insufficiency on COVID-19 128 outcomes using summary data from a meta-analysis of associations of vitamin D SNPs with the 129 dichotomous outcome of vitamin D deficiency versus sufficiency. 24 130

We constructed all genetic instruments for serum vitamin D levels based on independent 132 genetic loci associated with serum vitamin D levels at genome-wide significance (p < 5×10 -8 ). 133

For the primary analysis, we used a biologically plausible genetic instrument (instrument A) 134 consisting of SNPs in genetic loci that encode proteins in vitamin D transport and metabolism 135 (Supplemental Figure 1) , including the vitamin D binding protein (GC), 25 OH hydroxylase 136 (CYP2R1), 7-dehydrocholesterol reductase (DHCR7), and 24-hydroxylase (CYP24A1). All SNPs 137 included in Instrument A were associated with serum vitamin D at genome-wide significance in 138 the UK Biobank and replicated in the SUNLIGHT Consortium. 22,23 139

In secondary analyses, we expanded the genetic instrument to include additional genome-140 wide significant SNPs in loci with no known relation to vitamin D metabolism ( Figure 1) and standardized to a mean of 0 and standard deviation of 1, and SNP-vitamin D association 167 models were adjusted for age, sex, season of vitamin D measurement, vitamin D 168 supplementation, genotype batch, genotype array, and assessment center (as a proxy for latitude). 169

In the SUNLIGHT Consortium meta-analysis GWAS of serum vitamin D, serum vitamin D data 170 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. ; https://doi.org/10.1101/2021.01.29.21250759 doi: medRxiv preprint were log-transformed and SNP-vitamin D association models were adjusted for age, sex, BMI, 171 month of sample collection, cohort-specific variables such as geographical location and assay 172 batch, and genotype principal components. 22 In the SUNLIGHT Consortium meta-analysis of 173 SNP-risk of vitamin D deficiency/insufficiency associations, models were adjusted for age, sex, 174 BMI, and season, and genomic control was applied to control for population stratification. 24 175

We assessed the strength and validity of the genetic instruments for vitamin D by 177 calculating the F-statistic, 49 

We used genome-wide data for COVID-19 cases and comparison groups from the 189 COVID-19 Host Genetics Initiative, which is described elsewhere. 47 population controls, summary data from analyses limited to European ancestry participants were 215 also available. For these outcomes, we extracted summary data from both the mixed ancestry and 216 the European ancestry analyses for comparison and to address differences in ancestry 217 composition between vitamin D GWAS and COVID-19 Host Genetics Initiative sample 218 populations. 219

Our study design assumes that the potential effect of vitamin D nutritional status on 221 susceptibility to and severity of COVID-19 infection is the same across different COVID-19 risk 222 categories, including ancestry, age, sex, BMI, and smoking status. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. ; https://doi.org/10.1101/2021.01.29.21250759 doi: medRxiv preprint resembled those described for SNP-vitamin D associations in UK Biobank, 22 except that 238 genotype batch was not included as a covariate and vitamin D levels were not log-transformed. 239

We performed two-sample MR using the inverse variance weighted (IVW) method, 241 which assumes that pleiotropy is either non-existent or balanced (i.e., any associations of genetic 242 instrument SNPs with phenotypes other than vitamin D are randomly positive and negative such 243 that the mean pleiotropic effect is zero). 56 We used the MR-Egger intercept test to check for 244 evidence of directional pleiotropy, and performed sensitivity analyses using the MR-Egger, 245

weighted-median and weighted-mode methods. 57-59 The MR-Egger method relaxes the 246 assumption of no directional pleiotropy and corrects for pleiotropy-induced bias by allowing for 247 a nonzero intercept. 56,57 The weighted-median method assumes that at least 50% of the weight of 248 the genetic instrument comes from nonpleiotropic SNPs and produces an unbiased estimate so 249 long as less than 50% of SNPs have pleiotropic effects. 58 The weighted-mode method assumes 250 that the most common (modal) SNP-vitamin D effect is the true effect and therefore allows for 251 the inclusion of pleotropic SNPs without biasing the MR estimate. 59 Where evidence of 252 directional pleiotropy existed (MR-Egger intercept test P-value <0.05) we prioritized the MR 253 estimates from the MR-Egger, mode-weighted, and median-weighted analyses, otherwise we 254 prioritized the estimates from the IVW method. Results for our primary analysis are presented as 255 odds ratios and 95% confidence intervals (OR, 95% CI) for COVID-19 case versus comparator 256 per standard deviation increase in log-transformed serum vitamin D. The threshold for statistical 257 significance was set at a P-value < 0.05. All analyses were performed using R Studio version 258 1.2.1335 and the "TwoSampleMR" R package (https://github.com/MRCIEU/TwoSampleMR) 50 . 259 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We estimated potential bias under the null due to sample overlap between the UK 260 Biobank vitamin D GWAS and the COVID-19 Host Genetics Initiative using estimates of the 261 vitamin D-COVID-19 associations from observational studies, the percentage of sample overlap, 262 and the relative bias (reciprocal of the F-statistic), as previously described. 48 We compared SNP-263 vitamin D associations stratified by sex, age group, BMI category, and smoking status with 264

Pearson's correlation coefficients. 265

We calculated the minimum odds ratio detectable at 80% power for each COVID-19 266 outcome using the "mRnd" tool (https://shiny.cnsgenomics.com/mRnd/). 60 Characteristics of the genetic instruments for serum vitamin D, including contributing 280 SNPs, SNP-vitamin D associations in the UK Biobank, and F-statistics, indicate that instruments 281 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 2 ). The F-statistics for 283 instruments A, B, and C were respectively 53, 37, and 5 for the minimum sample size of 10,000 284 participants and 6,915, 4,746, and 600 for the maximum sample size of 1.3 million participants. 

We considered multiple case definitions, sample sizes, and ancestral compositions for the 291 COVID-19 case-control comparisons in our analysis ( Table 3) . 302

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

MR estimates (odds ratios and 95% confidence intervals) for the effect of genetically 304 predicted serum vitamin D on risk of COVID-19 outcomes, calculated separately for instruments 305 A, B, and C, are shown in Figure 2 and Table 3 . MR scatter plots and forest plots further 306 illustrating these results are shown in Supplementary Figure 2 . MR-Egger intercept tests for 307 pleiotropy were not statistically significant (MR-Egger intercept p-values > 0.1) for all 308 instruments and all outcomes (Table 3) Results of MR analyses limited to European ancestry participants, which we were able to 318 perform for the outcomes of COVID-19 versus population and hospitalized COVID-19 versus 319 population, were also non-significant (Supplementary Figure 3) . 320

For all outcomes, the MR-Egger intercept test showed little to no evidence of pleiotropy 321 (Table 3) . Nevertheless, we performed sensitivity analysis to explore possible pleiotropy using 322 the MR-Egger, weighted-median, and weighted-mode MR methods, and this analysis showed a 323 direct association of serum vitamin D with risk of hospitalized COVID-19 versus non-324 hospitalized COVID-19 (Supplemental Figure 4) . For this outcome, MR estimates from the MR-325 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 4 ). Results using the SUNLIGHT Consortium data were 337 consistent with results using the UK Biobank data; there was no evidence of pleiotropy for any 338 outcome (MR-Egger intercept p-value >0.1), and IVW MR estimates for the effect of genetically 339 predicted serum vitamin D on risk of COVID-19 outcomes were similar in magnitude and 340 direction and were not statistically significant (Supplementary Table 4 ). 341

A further sensitivity analysis evaluated the effect of genetically predicted vitamin D 343 deficiency and insufficiency on COVID-19 outcomes (Table 3, Figure 4 ). MR-Egger intercept 344 tests for pleiotropy were all non-significant (p-value > 0.1), and the IVW MR estimates did not 345 support an effect of long-term vitamin D deficiency or insufficiency on the risk of any of the 346 COVID-19 outcomes evaluated (Table 3, Figure 4) . 347 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. We used summary data from genome-wide analysis in the UK Biobank, SUNLIGHT 363

Consortium, and COVID-19 Host Genetics Initiative to conduct the first MR study of serum 364 vitamin D and COVID-19 outcomes. Although our study was powered to detect effects 365 comparable to those seen in observational studies of vitamin D and COVID-19, we found little to 366 no evidence of an effect of genetically predicted serum vitamin D levels on COVID-19 367 outcomes, including risk of COVID-19 infection, severe respiratory infection, and 368 hospitalization. Our results were robust to multiple genetic instruments for vitamin D and were 369 replicated using SNP-vitamin D association data from two independent samples. Results from 370 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We used the MR approach as an alternative way to address potential confounding. We (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. performing sensitivity analysis with alternative MR methods that address pleiotropy. We 407 explored potential threshold effects using genetic instruments for vitamin D deficiency and 408 insufficiency. Our findings were robust across all exploration, and, in triangulation with results 409 of the largest to date observational study of vitamin D and COVID-19, the findings help to 410 clarify the nature of the association of vitamin D with COVID-19 outcomes. 411

As in any MR study, the valid interpretation of our results rests on the MR assumptions 412 of adequate strength of the genetic instruments for vitamin D and absence of direct effects of the 413 instruments on COVID-19 outcomes and potential confounders (i.e., pleiotropy). Our 414 instruments easily met the MR standard for instrument strength (F-statistic >10) and we found no 415 evidence of pleiotropy from the MR-Egger intercept test. Our results were consistent across the 416 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. ; https://doi.org/10.1101/2021.01.29.21250759 doi: medRxiv preprint biologically plausible and expanded genetic instruments and largely similar in sensitivity 417 analysis using MR methods designed to address pleiotropy. While the findings in our study are 418 unlikely to be biased by pleiotropy, exhaustive tests for pleiotropy are challenging, making the 419 MR assumptions difficult to fully verify. 420

We used a two-sample MR approach, using estimates of associations of the genetic 421 instruments with vitamin D and with COVID-19 outcomes from two separate samples. This 422 approach maximizes sample size and reduces the likelihood of bias toward estimates from 423 observational studies 46 but requires that the two samples are drawn from similar populations. In 424 our study, the summary data for associations of the genetic instruments with vitamin D were 425 from analyses in European ancestry participants, while the data for associations of the genetic 426 instruments with COVID-19 outcomes were from analyses including up to 25% non-European 427 ancestry participants. Repeating the analysis with a subgroup of European-only participants for 428 two outcomes, COVID-19 versus population controls and hospitalized COVID-19 versus 429 population controls, indicated minimal impact of ancestral differences on MR estimates. 430

However, ancestry-specific data were not available for COVID-19 outcomes with larger 431

proportions of non-European ancestry participants, and the impact of ancestral differences could 432 not be fully explored. In sensitivity analyses using alternative MR methods that assume some 433 pleiotropy, findings indicated an association of higher vitamin D levels with higher risk of 434 hospitalization among COVID-19-infected individuals, the outcome with the highest proportion 435 of non-European ancestry participants. This finding could be driven by racial/ethnic disparities in 436 access to health care (i.e., hospitalized COVID-19 individuals may be more likely of European 437 ancestry and therefore have higher vitamin D status). We also found evidence for racial 438 differences in risk-factor stratified SNP-vitamin D associations. Our results suggest that SNP-439 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. ;  vitamin D associations are strongly correlated across sex, age, BMI, and smoking subgroups for 440 individuals of European ancestry, but not for individuals of African ancestry, although because 441 of small sample sizes for the African ancestry subgroups we are unable to draw firm conclusions. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. ;  of SNP-vitamin D associations by COVID-19 risk factors was approved by the Institutional 508

Review Board at RTI International. 509

Data sharing: All data used for this analysis are publicly available. Code implementing the 510 MR analysis is available upon request from the corresponding author. 511

Transparency: PAC is the corresponding author and guarantor for this paper and affirms that 512 the manuscript is an honest, accurate, and transparent account of the study being reported; that 513 no important aspects of the study have been omitted; and that any discrepancies from the study 514 as originally planned have been explained. 515

The Corresponding Author has the right to grant on behalf of all authors and does 516 grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in 517 perpetuity, in all forms, formats and media (whether known now or created in the future), to i) 518 publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution 519 into other languages, create adaptations, reprints, include within collections and create 520 summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) 521 based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion 522 of electronic links from the Contribution to third party material where-ever it may be located; 523 and, vi) licence any third party to do any or all of the above. 524 525 526 527 528 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. ; Table 1 Beta-vitD = beta coefficient for association of an additional effect allele with a SD change in serum vitamin D in the log scale; EA = effect allele; EAF = effect allele frequency; F-statistic = measure of instrument strength, calculated as described in the methods, shown for approximate minimum and maximum sample sizes across the COVID-19 outcomes; NEA = non-effect allele; P-vitD = P-value for the beta coefficient; SNP = single nucleotide polymorphism All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. ; https://doi.org/10.1101/2021.01.29.21250759 doi: medRxiv preprint 

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. ; https://doi.org/10.1101/2021.01.29.21250759 doi: medRxiv preprint

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. ; https://doi.org/10.1101/2021.01.29.21250759 doi: medRxiv preprint

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. ; https://doi.org/10.1101/2021.01.29.21250759 doi: medRxiv preprint

Vitamin D and inflammation

Vitamin D Insufficiency and Deficiency and 533 Mortality from Respiratory Diseases in a Cohort of Older Adults: Potential for Limiting the 534 Death Toll during and beyond the COVID-19 Pandemic?

Vitamin D receptor activation regulates microglia polarization and oxidative 536 stress in spontaneously hypertensive rats and angiotensin II-exposed microglial cells: Role 537 of renin-angiotensin system

Interactions of coronaviruses with ACE2, angiotensin II, and RAS 539 inhibitors-lessons from available evidence and insights into COVID-19

Calcitriol, the active form of vitamin D, is a promising candidate for 542 COVID-19 prophylaxis

Effect of calcifediol treatment and best available therapy versus 545 best available therapy on intensive care unit admission and mortality among patients 546 hospitalized for COVID-19: A pilot randomized clinical study

Vitamin D and survival in COVID-19 patients: A quasi-experimental 549 study

The role of vitamin D in the prevention of coronavirus 551 disease 2019 infection and mortality

COVID-19 fatalities, latitude, sunlight, and vitamin D

Avoidance of vitamin D deficiency to slow the COVID-19 pandemic

SARS-CoV-2 positivity 557 rates associated with circulating 25-hydroxyvitamin D levels

Association of Vitamin D Status and Other Clinical Characteristics 559 With COVID-19 Test Results

Does Serum Vitamin D Level Affect COVID-19 Infection and Its Severity?-A 563 Case-Control Study

Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL 565 reduced risk for adverse clinical outcomes in patients with COVID-19 infection

Interaction between age and vitamin D deficiency in severe COVID-19 568 infection

Vitamin D status and outcomes for hospitalised older patients with 570 COVID-19

COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment 572 Guidelines. COVID-19 Treatment Guidelines

Joint guidance on vitamin D in the era of COVID-19

Vitamin D concentrations and COVID-19 infection in UK Biobank

Genome-wide Association Study for Vitamin D Levels Reveals 69 580 Independent Loci

Genome-wide association study in 79,366 European-ancestry individuals 582 informs the genetic architecture of 25-hydroxyvitamin D levels

Common genetic determinants of vitamin D insufficiency: a genome-wide 585 association study

Genome-wide association study of circulating vitamin D levels

Transethnic Evaluation Identifies Low-Frequency Loci Associated With

CYP2R1 polymorphisms are important modulators of circulating 25-591 hydroxyvitamin D levels in elderly females with vitamin insufficiency, but not of the 592 response to vitamin D supplementation

East-Asian and Sub-Saharan African-ancestry populations

Vitamin D and C-Reactive Protein: A Mendelian Randomization 599 Study

Genetically low 601 vitamin D concentrations and increased mortality: Mendelian randomisation analysis in 602 three large cohorts

No evidence that 604 genetically reduced 25-hydroxyvitamin D is associated with increased risk of ischaemic 605 heart disease or myocardial infarction: a Mendelian randomization study

Vitamin D level and risk of systemic lupus erythematosus and 608 rheumatoid arthritis: a Mendelian randomization

Mendelian randomization analysis demonstrates that low vitamin D is 610 unlikely causative for pediatric asthma

Mendelian 612 Randomization Studies Do Not Support a Role for Vitamin D in Coronary Artery Disease

Vitamin D levels and susceptibility to asthma, elevated 615 immunoglobulin E levels, and atopic dermatitis: A Mendelian randomization study

Vitamin D and asthma: A Mendelian randomization study

Genetically decreased vitamin D and risk of Alzheimer disease

Association of vitamin D levels and risk of ovarian cancer: a Mendelian 623 randomization study

Vitamin D status, filaggrin genotype, and cardiovascular risk factors: a 625 Mendelian randomization approach

Investigating causality in the association between 25(OH)D and 627 schizophrenia

Vitamin D and mortality: a Mendelian randomization study

The role of genetic polymorphisms regulating vitamin D levels in 631 rheumatoid arthritis outcome: a Mendelian randomisation approach

Causal relationship between obesity and vitamin D status: bi-634 directional Mendelian randomization analysis of multiple cohorts

Association of vitamin D status with arterial blood pressure and 637 hypertension risk: a mendelian randomisation study

Association between circulating 25-hydroxyvitamin D and incident type 2 640 diabetes: a mendelian randomisation study

Mendelian Randomization Analysis With 642 Multiple Genetic Variants Using Summarized Data

The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host 644 genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic

Bias due to participant overlap in 647 two sample Mendelian randomization

Avoiding bias from weak 649 instruments in Mendelian randomization studies

The MR-Base platform supports systematic causal inference across the 651 human phenome

LDlink: a web-based application for exploring population-653 specific haplotype structure and linking correlated alleles of possible functional variants

Genetic association testing using the GENESIS R/Bioconductor 656 package

Inference of population structure using 658 multilocus genotype data

A global reference for human genetic variation

An integrated map of structural variation in 2,504 human genomes | Nature

Evaluating the potential role of pleiotropy in 663 Mendelian randomization studies

Mendelian randomization with invalid 665 instruments: effect estimation and bias detection through Egger regression

Mendelian Randomization with Some Invalid Instruments Using a Weighted Median 669 Estimator

Robust inference in summary data Mendelian 671 randomization via the zero modal pleiotropy assumption

Calculating statistical power in 674 Mendelian randomization studies

Genome-wide Association Study for Vitamin D Levels Reveals 69 676 Independent Loci

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

Contributor and Guarantor Confirmation: The study was designed and conceived by BKP, 487 PAC and AGC. The MR analyses were performed by BKP in close consultation with PAC. The 488 follow-up stratified analyses of SNP-vitamin D associations were performed by NG. The 489 manuscript was drafted by BKP and PAC, and edited with input from AGC, DBH and NG. All Competing interests: All authors have completed the ICMJE uniform disclosure form at 500 www.icmje.org/coi_disclosure.pdf and declare: no support from any organization for the 501 submitted work; BKP was supported by the National Institutes of Health during the conduct of 502 the study, AGC, DBH and PAC report receiving grants from the National Institutes of Health 503 during the conduct of the study; no other relationships or activities that could appear to have 504 influenced the submitted work. 505Ethics approval: The main analysis conducted in this study used publicly available summary 506 data and did not require ethical approval. The use of UK Biobank data for the stratified analysis 507